| Patent application number | Description | Published |
|---|
| 20080241142 | Neuropilin/VEGF-C/VEGFR-3 Materials and Methods - The present invention relates to identifying modulators of VEGF-C or VEGF-D ligand binding to the nervous system transmembrane protein neuropilin-2 and materials and methods for detecting said modulators. | 10-02-2008 |
| 20080241152 | Vascular Endothelial Growth Factor C (VEGF-C) Protein and Gene, Mutants Thereof, and Uses Thereof - Provided are purified and isolated VEGF-C polypeptides capable of binding to at least one of KDR receptor tyrosine kinase (VEGFR-2) and Flt4 receptor tyrosine kinase (VEGFR-3); analogs of such peptides that have VEGF-C-like or VEGF-like biological activities or that are VEGF or VEGF-C inhibitors; polynucleotides encoding the polypeptides; vectors and host cells that embody the polynucleotides; pharmaceutical compositions and diagnostic reagents comprising the polypeptides; and methods of making and using the polypeptides. | 10-02-2008 |
| 20080241153 | Vascular Endothelial Growth Factor C (VEGF-C) Protein and Gene, Mutants Thereof, and Uses Thereof - Provided are purified and isolated VEGF-C polypeptides capable of binding to at least one of KDR receptor tyrosine kinase (VEGFR-2) and Flt4 receptor tyrosine kinase (VEGFR-3); analogs of such peptides that have VEGF-C-like or VEGF-like biological activities or that are VEGF or VEGF-C inhibitors; polynucleotides encoding the polypeptides; vectors and host cells that embody the polynucleotides; pharmaceutical compositions and diagnostic reagents comprising the polypeptides; and methods of making and using the polypeptides. | 10-02-2008 |
| 20080267924 | AUTOLOGOUS LYMPH NODE TRANSFER IN COMBINATION WITH VEGF-C OR VEGF-D GROWTH FACTOR THERAPY TO TREAT SECONDARY LYMPHEDEMA AND TO IMPROVE RECONSTRUCTIVE SURGERY - The present invention provides materials and methods for repairing tissue and using vascular endothelial growth factor C (VEGF-C) genes and/or proteins. Methods and materials related to the use of VEGF-C for the reduction of edema and improvement of skin perfusion is provided. Also provided is are materials and methods for using VEGF-C before, during, and after reconstructive surgery. | 10-30-2008 |
| 20080267956 | GROWTH FACTOR ANTAGONISTS FOR ORGAN TRANSPLANT ALLOIMMUNITY AND ARTERIOSCLEROSIS - The present invention provides materials and methods for antagonizing the function of vascular endothelial growth factor receptors, platelet derived growth factor receptors and other receptors, to prevent, inhibit, or ameliorate allograft rejection or arteriosclerosis in organisms that receive an organ transplant. | 10-30-2008 |
| 20080317723 | LYMPHATIC ENDOTHELIAL CELLS MATERIALS AND METHODS - The present invention is directed to methods and compositions for isolating lymphatic endothelial cells from a mixed population of cells. More particularly, the inventors have found that certain antibodies that recognize the extracellular domain of VEGFR-3 can be used to specifically isolated lymphatic endothelial cells substantially free of other contaminating non-lymphatic endothelial cells. Methods and compositions for producing such cells and using such cells are described. | 12-25-2008 |
| 20090017011 | MODULATION OF VEGF-C/VEGFR-3 INTERACTIONS IN THE TREATMENT OF RHEUMATOID ARTHRITIS - The present invention relates to methods for treating an individual exhibiting symptoms of chronic arthridites, as identified by an elevated level of VEGF-C expression at synovial sites, and provides materials and methods for the modulation of VEGF-C/VEGFR-3 ligand-receptor interactions as a treatment for chronic arthridites. | 01-15-2009 |
| 20090104198 | VASCULAR ENDOTHELIAL GROWTH FACTOR C (VEGF-C) PROTEIN AND GENE, MUTANTS THEREOF, AND USES THEREOF - Provided are purified and isolated VEGF-C polypeptides capable of binding to at least one of KDR receptor tyrosine kinase (VEGFR-2) and Flt4 receptor tyrosine kinase (VEGFR-3); analogs of such peptides that have VEGF-C-like or VEGF-like biological activities or that are VEGF or VEGF-C inhibitors; polynucleotides encoding the polypeptides; vectors and host cells that embody the polynucleotides; pharmaceutical compositions and diagnostic reagents comprising the polypeptides; and methods of making and using the polypeptides. | 04-23-2009 |
| 20090155268 | Growth Factor Binding Constructs Materials and Methods - The present invention provides materials and methods for antagonizing the function of vascular endothelial growth factor receptors, platelet derived growth factor receptors and other receptors. Soluble binding constructs able to bind vascular endothelial growth factors, platelet derived growth factors, and other ligands are provided. | 06-18-2009 |
| 20090191166 | SCREENING AND THERAPY FOR LYMPHATIC DISORDERS INVOLVING THE FLT4 RECEPTOR TYROSINE KINASE (VEGFR-3) - The present invention provides materials and methods for screening for and treating hereditary lymphedema in human subjects. | 07-30-2009 |
| 20090202491 | Method for modulating, regulating and/or stabilizing angiogenesis - A method of modulating, regulating and/or stabilizing angiogenesis in a mammal in need thereof, in which the PDGF-D level or activity or both in the mammal are modulated or increased. In preferred embodiments, an active PDGF-D polypeptide, or a polynucleotide encoding an active PDGF-D is administered to the mammal, preferably at a location where angiogenesis modulation or stabilization is desired. The PDGF-D is advantageously co-administered with an angiogenic growth factor, such as a member of the VEGF family of growth factors, in particular VEGF-E. The claimed method inhibits leakage of blood vessels and is useful, inter alia, for treatment of edemas. | 08-13-2009 |
| 20090214496 | BMX/ETK TYROSINE KINASE GENE THERAPY MATERIALS AND METHODS - The present invention relates to materials and methods for the treatment of arterial diseases having impaired arteriogenesis and angiogenesis. More particularly, the invention provides materials and methods for treating arterial disease using a gene therapy vector expressing Bmx tyrosine kinase. | 08-27-2009 |
| 20090318352 | Materials and Methods Involving Hybrid Vascular Endothelial Growth Factor DNAs and Proteins - The present invention provides polypeptides that bind cellular receptors for vascular endothelial growth factor polypeptides; polynucleotides encoding such polypeptides; compositions comprising the polypeptides and polynucleotides; and methods and uses involving the foregoing. Some polypeptides of the invention exhibit unique receptor binding profiles compared to known, naturally occurring vascular endothelial growth factors. | 12-24-2009 |
| 20100041605 | Use of VEGF-C or VEGF-D in Reconstructive Surgery - The present invention provides materials and methods for repairing tissue and using vascular endothelial growth factor C (VEGF-C) genes and/or proteins. Methods and materials related to the use of VEGF-C for the reduction of edema and improvement of skin perfusion is provided. Also provided is are materials and methods for using VEGF-C before, during, and after reconstructive surgery. | 02-18-2010 |
| 20100278736 | FLT4 (VEGFR-3) as a Target for Tumor Imaging and Anti-Tumor Therapy - The present invention provide purified Flt4 receptor tyrosine kinase polypeptides and fragments thereof, polynucleotides encoding such polypeptides, antibodies that specifically bind such polypeptides, and uses therefor. | 11-04-2010 |
| 20110059890 | EXPRESSION VECTORS AND CELL LINES EXPRESSING VASCULAR ENDOTHELIAL GROWTH FACTOR D, AND METHOD OF TREATING MELANOMAS - This invention relates to expression vectors comprising VEGF-D and its biologically active derivatives, cell lines stably expressing VEGF-D and its biologically active derivatives, and to a method of making a polypeptide using these expression vectors and host cells. The invention also relates to a method for treating and alleviating melanomas or tumors expressing VEGF-D and various diseases. | 03-10-2011 |
| 20110135649 | Vascular Endothelial Growth Factor C (VEGF-C) Protein and Gene, Mutants Thereof, and Uses Thereof - Provided are purified and isolated VEGF-C polypeptides capable of binding to at least one of KDR receptor tyrosine kinase (VEGFR-2) and Flt4 receptor tyrosine kinase (VEGFR-3); analogs of such peptides that have VEGF-C-like or VEGF-like biological activities or that are VEGF or VEGF-C inhibitors; polynucleotides encoding the polypeptides; vectors and host cells that embody the polynucleotides; pharmaceutical compositions and diagnostic reagents comprising the polypeptides; and methods of making and using the polypeptides. Methods of inhibiting endothelial cell proliferation are also provided. | 06-09-2011 |
